Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on ORKA. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Finally, Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $20.31 on Friday. The company has a 50 day simple moving average of $24.55. The stock has a market capitalization of $710.83 million, a P/E ratio of -3.24 and a beta of 0.78. Oruka Therapeutics has a 1-year low of $18.20 and a 1-year high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics during the third quarter valued at $1,037,000. Wellington Management Group LLP purchased a new position in Oruka Therapeutics in the 3rd quarter valued at about $2,013,000. Point72 Asset Management L.P. acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $11,822,000. RTW Investments LP purchased a new stake in shares of Oruka Therapeutics during the third quarter worth about $45,359,000. Finally, FMR LLC acquired a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $114,763,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.